GLPG3667
TYK2
Small molecule
DMSLE
Focusing on high unmet medical needs, we synergize compelling science, technology, and collaborative approaches to create a deep pipeline of potential best-in-class therapies.
DMSLE
SLE: Systemic lupus erythematosus; DM: Dermatomyositis
We are advancing a pipeline of t cell engagers, anchored by gamgertamig, a potential first and best-in-class BCMAxCD3 T cell engager for autoimmune indications. Gamgertamig is being developed in collaboration with Gilead. Gilead also has the right to opt-into a 50/50 profit share on the preclinical T cell engager programs after clinical proof of concept.
AICSAIAIBD
Undisclosed
Note: AIC, Autoimmune Cytopenia; SAI, Seropositive Autoimmune Diseases; AIBD, Autoimmune Bullous Diseases; AIHA, autoimmune hemolytic anemia; ITP, immune thrombocytopenia; APS, antiphospholipid syndrome; SjD, Sjogren’s disease; IIM, Idiopathic inflammatory myopathy; Myositis, Dermatomyositis, Polymyositis, Immune Mediated Necrotizing Myopathy, Anti-synthetase syndrome; PV, pemphigus vulgaris; PF, pemphigus foliaceus; IIS, investigator-initiated study
In October 2025, the Lakefront Board of Directors decided to pursue an intention to wind down the Company’s cell therapy activities. Following completion of consultations with works councils in Belgium and the Netherlands, implementation of the wind-down was initiated in January 2026. Exiting the cell therapy business reflects Lakefront’s commitment to defining a clear and sustainable path forward and focusing its efforts where it can create the greatest patient and shareholder value.
At Lakefront Biotherapeutics, we organize clinical trials in various therapeutic areas, conducting research that paves the way for innovative medicines.